Clinical Trials Browser

OTHER × Breast Neoplasms × pembrolizumab × Clear all

NCT03632941 2026-06-04

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Phase 2 Terminated

8 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT06351332 2026-06-04

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Phase 1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05203445 2026-05-29

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Phase 2 Active not recruiting

6 enrolled 9 charts

Breast Neoplasms

NCT03789097 2026-05-22

Vaccination With Flt3L, Radiation, and Poly-ICLC

Phase 1/2 Completed

BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase 2 Active not recruiting

Breast Neoplasms

NCT06246968 2026-05-20

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07178730 2026-05-06

ADAPT-TN-IV

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05645380 2026-04-28

NeoTRACT

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02734290 2026-04-24

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04373031 2026-04-24

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Phase 2 Active not recruiting

12 enrolled 11 charts

Breast Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03366844 2026-04-20

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Phase 1/2 Active not recruiting

66 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491226 2026-04-20

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07015853 2026-04-20

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03435952 2026-04-16

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Phase 1 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase 1 Recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT06604858 2026-04-07

TELESCOPE

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Phase 2 Active not recruiting

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT03449238 2026-03-30

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT03546686 2026-03-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT07486687 2026-03-20

PLANET

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03272334 2026-02-27

Breast-47

Phase 1/2 Active not recruiting

22 enrolled 15 charts

Breast Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04265872 2026-02-12

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms

NCT07188246 2026-02-11

BRINK

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03237572 2026-02-09

Breast-48

Phase 1 Terminated

13 enrolled 10 charts

Breast Neoplasms

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT02999477 2026-01-29

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Phase 1 Completed

32 enrolled 23 charts

Breast Neoplasms

NCT03804944 2026-01-28

CBCV

Phase 2 Recruiting

Breast Neoplasms

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Phase 2 Active not recruiting

110 enrolled 26 charts

Breast Neoplasms

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT03393845 2026-01-02

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms

NCT03225547 2025-12-23

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03095352 2025-12-22

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Phase 2 Completed

76 enrolled 14 charts

Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06078384 2025-11-17

ETNA

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02414269 2025-10-08

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1/2 Active not recruiting

BreastOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis

NCT03362060 2025-10-01

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06606730 2025-08-26

OPT-PEMBRO

Phase 3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491083 2025-07-25

ComPACT

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms